Jennifer Riley - 26 Feb 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Reporting relationship: Chief Strategy Officer
Issuer ticker: AVTX
Reported as of: 26 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2026, 16:23:32 UTC
Prior SEC filing: 12 Dec 2025
Next SEC filing: 26 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Sullivan, Attorney-in-Fact

Key filing fact

Jennifer Riley filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 02 Mar 2026.

Key facts

This page summarizes Jennifer Riley's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2026, 16:23.

Change

Previous filing in this sequence was filed on 12 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002047607 Primary reporting owner

Riley Jennifer

Relationship: Chief Strategy Officer
Address: C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
Signature: /s/ Christopher Sullivan, Attorney-in-Fact
Signature date: 02 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +95,000
Change %
Price: $0.000000
Shares after: 95,000
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 95,000
Exercise price: $17.64
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.